01—Abstract
Summary
Summary of the 10-Q filed August 2, 2024. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals Inc. reported its second-quarter and first-half 2024 financial results, highlighting continued revenue growth driven by its cystic fibrosis (CF) franchise, particularly TRIKAFTA/KAFTRIO.
Despite a significant net loss for the period, largely due to a substantial acquired in-process research and development (AIPR&D) charge related to the acquisition of Alpine Immune Sciences, Inc., the company's core product revenue remains strong. Key developments include the acquisition of Alpine, which significantly impacted the quarter's financials but brought povetacicept into the pipeline for kidney diseases.
Vertex is also progressing with its non-CF pipeline, with notable advancements in its sickle cell disease therapy, CASGEVY, and upcoming potential launches for vanzacaftor/tezacaftor/deutivacaftor in CF and suzetrigine for acute pain. The company's liquidity remains robust, although cash reserves have decreased due to the Alpine acquisition.
02—Key points
Key Highlights
- Reported net product revenues of $2.65 billion for Q2 2024, a 6% increase year-over-year, driven by strong performance of TRIKAFTA/KAFTRIO. First-half 2024 revenues reached $5.34 billion, up 10%.
- Recorded a net loss of $3.59 billion for Q2 2024 ($13.92 per diluted share), compared to a net income of $915.7 million ($3.52 per diluted share) in Q2 2023. The loss was primarily due to a $4.45 billion charge for acquired in-process research and development related to the Alpine acquisition.
- Completed the acquisition of Alpine Immune Sciences for approximately $5.0 billion, adding povetacicept, a potential best-in-class treatment for IgA nephropathy, to its pipeline. This acquisition was accounted for as an asset acquisition, resulting in a significant AIPR&D expense.
- Continued progress in the development and regulatory filings for key pipeline assets, including vanzacaftor/tezacaftor/deutivacaftor for CF (potential launch Jan 2025) and suzetrigine for acute pain (potential launch Jan 2025).
- CASGEVY, for sickle cell disease and beta thalassemia, has received approvals in the U.S., EU, UK, Saudi Arabia, and Bahrain, with ongoing global regulatory submissions and treatment center activations.
- Cash, cash equivalents, and marketable securities decreased to $10.2 billion as of June 30, 2024, from $13.7 billion as of December 31, 2023, primarily due to the cash used for the Alpine acquisition.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q2 FY2024, Vertex Pharmaceuticals Inc lost $1.36.
- Revenue$2.65B100.0%
- Cost of revenue−$371.9M14.1%
- Gross profit$2.27B85.9%
- Operating costs−$5.79B218.8%
- Operating income−$3.51B132.9%
- Interest, other & tax−$78.9M3.0%
- Net income−$3.59B135.8%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 2, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $2.65B$2.49B | +6.1% |
| Cost of Revenue | $371.90M$308.60M | +20.5% |
| Gross Profit | $2.27B$2.18B | +4.1% |
| SG&A Expenses | $372.20M$262.60M | +41.7% |
| Operating Expenses | $6.16B$1.47B | +320.0% |
| Operating Income | -$3.51B$1.03B | −442.4% |
| Net Income | -$3.59B$915.70M | −492.4% |
| EPS (Basic) | $-13.92$3.55 | −492.1% |
| EPS (Diluted) | $-13.92$3.52 | −495.5% |
| Shares Outstanding (Basic) | 258.10M257.70M | +0.2% |
| Shares Outstanding (Diluted) | 258.10M260.40M | −0.9% |
05—Questions
Frequently Asked Questions
What is the primary driver behind the significant net loss in the current quarter?
The substantial net loss of $3.59 billion in the second quarter of 2024 is primarily due to a $4.45 billion charge for acquired in-process research and development (AIPR&D). This charge is a result of Vertex's acquisition of Alpine Immune Sciences, Inc., which was accounted for as an asset acquisition.
How is the company's core revenue performing despite the net loss?
Vertex's core product revenues continue to show strong growth. Net revenues for the second quarter of 2024 increased by 6% year-over-year to $2.65 billion, driven mainly by the performance of its cystic fibrosis (CF) medicine TRIKAFTA/KAFTRIO. For the first half of 2024, revenues grew 10% to $5.34 billion.
What are the key implications of the Alpine Immune Sciences acquisition?
The acquisition of Alpine for approximately $5.0 billion brings povetacicept, a promising asset for treating IgA nephropathy and other autoimmune kidney diseases, into Vertex's pipeline. While it significantly impacted the current quarter's financials due to an AIPR&D charge, it strengthens Vertex's diversification beyond its CF franchise and adds a novel therapeutic candidate.
What are the near-term commercialization prospects for Vertex?
Vertex is preparing for the near-term launch of vanzacaftor/tezacaftor/deutivacaftor for cystic fibrosis, with FDA and EMA submissions underway and target action dates in early 2025. Additionally, suzetrigine for acute pain has received FDA Priority Review, with a target action date in January 2025. The company also continues to expand access to its sickle cell disease therapy, CASGEVY.
06—Continue